AI Article Synopsis

  • Thirteen isopropyl chalcones were synthesized and tested for their ability to inhibit monoamine oxidase (MAO), finding that all compounds were more effective against MAO-B than MAO-A.
  • The most potent inhibitor of MAO-B was identified as having an IC value of 0.032 μM, showing high selectivity over MAO-A, while another compound was the strongest inhibitor for MAO-A at 0.310 μM.
  • Kinetic studies indicated that specific compounds exhibited reversible inhibition for both MAO-A and MAO-B, highlighting their potential use in treating Parkinson's disease.

Article Abstract

Thirteen isopropyl chalcones () were synthesized and evaluated for their inhibitory activity against monoamine oxidase (MAO). All compounds inhibited MAO-B more effectively than MAO-A. Compound most potently inhibited MAO-B with an IC value of 0.032 μM, similar to that of (IC = 0.035 μM) and with high selectivity index (SI) values for MAO-B over MAO-A (SI = 49.75 and 353.23, respectively). The -OH () or -F () group at the para position on the A ring provided higher MAO-B inhibition than that of the other substituents (-OH ≥ -F > -Cl > -Br > -OCHCH > -CF). On the other hand, compound most potently inhibited MAO-A with an IC value of 0.310 μM and effectively MAO-B (IC = 0.074 μM). The Br-containing thiophene substituent () instead of the A ring showed the highest MAO-A inhibition. In a kinetic study, values of compounds and for MAO-B were 0.076 ± 0.001 and 0.027 ± 0.002 μM, respectively, and that of for MAO-A was 0.016 ± 0.005 μM. A reversibility study showed that and were reversible inhibitors of MAO-B and was a reversible inhibitor of MAO-A. In docking and molecular dynamics, the hydroxyl group of and two hydrogen bonds contributed to the stability of the protein-ligand complex. These results suggest that and are potent reversible selective MAO-B inhibitors and can be used for the treatment of Parkinson's disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947953PMC
http://dx.doi.org/10.1021/acsomega.2c07694DOI Listing

Publication Analysis

Top Keywords

mao-b
9
selective mao-b
8
mao-b inhibitors
8
inhibitors treatment
8
treatment parkinson's
8
inhibited mao-b
8
compound potently
8
potently inhibited
8
mao-a
6
μm
6

Similar Publications

The pathology of Alzheimer's disease (AD) is complex due to its multifactorial nature and single targeting drugs proved inefficient. A series of novel 4-N-substituted-2-phenylquinazoline derivatives was designed and synthesized as potential multi-target directed ligands (MTDLs) through dual inhibition of AChE and MAO-B enzymes along with Aβ aggregation inhibition for the treatment of AD. Two compounds in the series, VAV-8 and VAV-19 were found to be the most potent inhibitors of both AChE and MAO-B enzymes and moderate inhibitor of Aβ, with good thermodynamic stability at the binding pocket of the enzymes.

View Article and Find Full Text PDF

Introduction: Prasinezumab was shown to potentially delay motor progression in individuals with early-stage Parkinson's disease (PD) who were either treatment-naïve or on monoamine oxidase type B inhibitor (MAO-Bi) therapy in the PASADENA study. We report the rationale, design, and baseline patient characteristics of the PADOVA study, designed to evaluate prasinezumab in an early-stage PD population receiving standard-of-care (SOC) symptomatic medications.

Methods: PADOVA (NCT04777331) is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, in which individuals with early-stage PD on SOC stable symptomatic monotherapy (levodopa or MAO-Bi) receive intravenous prasinezumab 1500 mg every 4 weeks.

View Article and Find Full Text PDF

Chronic stress exposure has been widely recognized as a significant contributor to numerous central nervous system (CNS) disorders, leading to debilitating behavioral changes such as anxiety, depression, and cognitive impairments. The prolonged activation of the hypothalamic-pituitary-adrenal (HPA) axis during chronic stress disrupts the neuroendocrine balance and has detrimental effects on neuronal function and survival. () Gaertn.

View Article and Find Full Text PDF

Monoamine oxidase B (MAO-B) inhibitors are widely used as part of combination drug therapy for Parkinson's disease. As demonstrated in both in vitro and in vivo experiments, the monoterpenoid Prottremine and some of its derivatives exhibit high antiparkinsonian activity. In this study, the inhibitory activity of Prottremine and its derivatives (including 14 new 9-- and -derivatives) against MAO-A and MAO-B enzymes has been investigated for the first time.

View Article and Find Full Text PDF

Monoamine oxidase B (MAO-B) is a key enzyme in the mitochondrial outer membrane, pivotal for the oxidative deamination of biogenic amines. Its overexpression has been implicated in the pathogenesis of several cancers, including glioblastoma and colorectal, lung, renal, and bladder cancers, primarily through the increased production of reactive oxygen species (ROS). Inhibition of MAO-B impedes cell proliferation, making it a potential therapeutic target.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!